MinervaX announces that it today has enrolled and dosed the last of 240 subjects in it Phase I Part B Dose-confirmation trial on its Group B Streptococcal vaccine GBS-NN.
- MinervaX Provides Clinical Update on its Maternal GBS Vaccine 14/02/2022
- MVX0004 Phase II 11/02/2022
- MinervaX provides clinical and leadership update 07/10/2021
- MVX0003 Phase I 01/02/2021
- MinervaX announces completion of 47.4 mEUR financing 15/12/2020